КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ IgA-НЕФРОПАТИИ
Аннотация
Представленные рекомендации обобщают принятые в мире подходы к диагностике и лечению одного из наиболее распространенных видов гломерулонефрита - IgA-нефропатии. Они вставлены в соответствии с современными международными [1] и отечественными [2] рекомендациями по лечению гломерулонефритов, основанными на результатах систематических обзоров и мета-анализов релевантных клинических исследований, а также накопленном на сегодняшний отечественном опыте адаптации международных рекомендаций к условиям Российского здравоохранения. Данные Рекомендации не следует рассматривать в качестве стандарта оказания медицинской помощи, поскольку в существующей клинической практике объем диагностики и лечения определяется индивидуальными особенностями пациентов, доступностью различных лекарственных средств и спецификой конкретного лечебного учреждения. За уместность применения данных Рекомендаций в конкретной ситуации несет ответственность использующий их врач.
Об авторах
Е. М. Шилов
ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Министерства здравоохранения РФ
Россия
Россия
И. Н. Бобкова
ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Министерства здравоохранения РФ
Россия
Россия
И. Б. Колина
ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Министерства здравоохранения РФ
Россия
Россия
Е. С. Камышова
ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Министерства здравоохранения РФ
Россия
Россия
Список литературы
1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Capter 10: immunoglobulin A nephropathy. Kidney Int Suppl 2012;2: S209-S217
2. Мухин Н.А, Козловская Л.В, Шилов Е.М. и др. Рациональная фармакотерапия в нефрологии. Рук. для практикующих врачей. Литерра, М., 2006; 896 с.
3. Li P.K, Ho K.K, Szeto C.C. et al. Prognostic indicators of IgA nephropathy in the Chinese-clinical and pathological perspectives. Nephrol Dial Transplant 2002; 17: 64-69
4. Nair R, Walker P.D. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 2006; 69:1455-1458
5. Maisonneuve P, Agodoa L, Gellert R. et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000;35:157-165
6. Waldherr R, Rambausek M, Duncker W.D, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4: 943-946
7. Suzuki K, Honda K, Tanabe K. et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63: 2286-2294
8. Jennette J.C, Wall S.D, Wilkman A.S. Low incidence of IgA nephropathy in blacks. Kidney Int 1985; 28:944-950
9. DAmico G, Colasanti G, Barbiano di Belgioioso G. et al. Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients. Semin Nephrol 1987; 7: 355-358
10. Ibels L.S, Gyory A.Z. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine (Baltimore) 1994; 73: 79-102
11. Choy B.Y , Chan T.M, Lai K.N. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6: 2535-2542
12. Moroni G, Longhi S, Quaglini S, et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant 2013; 28: 1305-1314
13. Suzuki H, Kiryluk K, Novak J. et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22: 1795-1803
14. Novak J, Julian B.A, Mestecky J, Renfrow M.B. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Im-munopathol 2012; 34: 365-382
15. Boyd J.K, Cheung C.K, Molyneux K. et al. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 2012; 81: 833-843
16. Gharavi A.G, Yan Y, Scolari F. et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000; 26: 354-357
17. Bisceglia L, Cerullo G, Forabosco P. et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet 2006; 79:1130-1134
18. http://www.uptodate.com/contents/treatment-and-prognosis-of-iga-nephropathy?source=related_link
19. Szeto C.C, Lai F.M, To K.F. et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110: 434-437
20. Donadio J.V, Grande J.P. IgA nephropathy. N Engl J Med 2002; 347: 738-748
21. Wyatt R.J, Julian B.A. IgA nephropathy. N Engl J Med 2013; 368: 2402-2414
22. Habib R, Niaudet P, Levy M. Schoenlein-Henoch purpura nephritis and IgA nephropathy. In: Tisher C, Brenner B.M, eds. Renal pathology. Philadelphia: J.B. Lippincott, 1994: 472-523
23. DAmico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992; 20: 315-323
24. Berthoux F, Mohey H, Laurent B. et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011; 22: 752-761
25. Wakai K, Kawamura T, Endoh M. et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006; 21: 2800-2808
26. Coppo R, DAmico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005; 18: 503-512
27. Bartosik L.P, Lajoie G, Sugar L, Cattran D.C. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735
28. Ikee R, Kobayashi S, Saigusa T. et al. Impact of hypertension and hypertension-related vascular lesions in IgA nephropathy. Hypertens Res 2006; 29: 15-22
29. Donadio J.V, Bergstralh E.J, Grande J.P, Rademcher D.M. Proteinuria patterns and their association with subsequent endstage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002; 17: 1197-1203
30. Le W, Liang S, Hu Y. et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 2012; 27: 1479-1485
31. Maixnerova D, Bauerova L, Skibova J. et al. The retrospective analysis of 343 Czech patients with IgA nephropathy-one centre experience. Nephrol Dial Transplant 2012; 27: 1492-1498
32. Harden P.N, Geddes C, Rowe P.A. et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345: 1540-1542
33. Hunley T.E, Julian B.A, Phillips J.A. 3rd. et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996; 49: 571-577
34. Bonnet F, Deprele C, Sassolas A. et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720-727
35. Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA 48. nephropathy. Nephrol Dial Transplant 2000; 15: 34-42
36. Yamamoto R, Nagasawa Y, Shoji T et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis 2010; 56: 313-324
37. Daniel L, Saingra Y, Giorgi R et al. Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis 2000; 35: 13-20.
38. Weber C.L, Rose C.L, Magil A.B. Focal segmental glomerulosclerosis in mild IgA nephropathy: a clinical-pathologic study. Nephrol Dial Transplant 2009; 24: 483-488
39. Lee H.S, Lee M.S, Lee S.M. et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant 2005; 20: 342-348
40. Manno C, Strippoli G.F, DAltri C. et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis 2007; 49: 763-775
41. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545
42. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook H.T. et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556
43. Reid S, Cawthon P.M, Craig J.C. et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011; CD003962
44. Kunz R, Friedrich C, Wolbers M, Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48
45. Kanno Y Okada H, Saruta T, Suzuki H. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 2000; 54: 360-365
46. Praga M, Gutiérrez E, Gonzalez E. et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583
47. Li P.K, Leung C.B, Chow K.M. et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47: 751-760
48. Coppo R, Peruzzi L, Amore A et al. IgACE: a placebocontrolled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-1888
49. Cattran D.C. Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy? J Am Soc Nephrol 2007; 18: 1633-1634
50. Li P.K, Kwan B.C, Chow K.M. et al. Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor. Am J Med 2013; 126: 162-168
51. Catapano F, Chiodini P, De Nicola L. et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-485
52. Donadio J.V. Jr, Bergstralh E.J, Offord K.P. et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331: 1194-1199
53. Donadio J.V. Jr, Larson T.S, Bergstralh E.J, Grande J.P. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001; 12: 791-799
54. Ferraro P.M, Ferraccioli G.F, Gambaro G. et al. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2009; 24: 156-160
55. Floege J, Eitner F. Present and future therapy options in IgA-nephropathy. J Nephrol 2005; 18: 354-361
56. Locatelli F, Del Vecchio L, Pozzi C. The patient with IgA glomerulonephritis-what is the role of steroid treatment? Nephrol Dial Transplant 1999; 14: 1057-1060
57. Lv J, Xu D, Perkovic V. et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012; 23: 1108-1114
58. Pozzi C, Andrulli S, Del Vecchio L. et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157-163
59. Manno C, Torres D.D, Rossini M. et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3694-3701
60. Lai K.N, Lai F.M, Ho C.P, Chan K.W. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174-180
61. Mustonen J, Pasternack A, Rantala I. The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 1983; 20: 172-176
62. Cheng I.K, Chan K.W, Chan M.K. Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission. Am J Kidney Dis 1989; 14: 361-364
63. Walker R.G, Yu S.H, Owen J.E, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990; 34: 103-107
64. Ballardie F.W, Roberts I.S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148
65. Yoshikawa N, Honda M, Iijima K et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 2006; 1: 511-517
66. Pozzi C, Andrulli S, Pani A et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 2010; 21: 1783-1790
67. Floege J, Eitner F. Combined immunosuppression in high-risk patients with IgA nephropathy? J Am Soc Nephrol 2010; 21: 1604-1606
68. Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol 2011; 22: 1785-1794
69. Kamei K, Nakanishi K, Ito S. et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 2011; 6: 1301-1307
70. Maes B.D, Oyen R, Claes K. et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebocontrolled randomized study. Kidney Int 2004; 65: 1842-1849
71. Tang S.C, Tang A.W, Wong S.S. et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 2010; 77: 543-549
72. Dal Canton A, Amore A, Barbano G et al. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropa thy: a multicenter, randomised, controlled study. J Nephrol 2005; 18: 136-140
73. Lai K.N, Lai F.M, Li P.K, Vallance-Owen J. Cyclosporin treatment of IgA nephropathy: a short term controlled trial. Br Med J (Clin Res Ed) 1987; 295: 1165-1168
74. Roccatello D, Ferro M, Coppo R. et al. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant 1995; 10: 2054-2059
75. McIntyre C.W, Fluck R.J, Lambie S.H. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. Clin Nephrol 2001; 56: 193-198
76. Tumlin J.A, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003; 18: 1321-1329
77. Xie X , Nishi S, Ueno M. et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63: 1861-1867
78. Rasche F.M, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999; 51: 147-152
79. Kawamura T, Yoshimura M, Miyazaki Y. et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant 2014; 29: 1546-1553
80. Zand L, Fervenza F.C. Does tonsillectomy have a role in the treatment of patients with immunoglobulin A nephropathy? Nephrol Dial Transplant 2014; 29:1456-1459
81. Wang X, Chen J, Wang Y et al. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transplant 2011; 26: 1923-1931
82. Ferri C, Puccini R, Longombardo G. et al. Low-antigen-content diet in the treatment of patients with IgA nephropathy. Nephrol Dial Transplant 1993; 8: 1193-1198
83. Coppo R, Roccatello D, Amore A. et al. Effects of a glutenfree diet in primary IgA nephropathy. Clin Nephrol 1990; 33: 72-86
Рецензия
Для цитирования:
Шилов Е.М., Бобкова И.Н., Колина И.Б., Камышова Е.С. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ IgA-НЕФРОПАТИИ. Нефрология. 2015;19(6):83-92.
For citation:
Shilov E.M., Bobkova I.N., Kolina I.B., Kamishova E.S. CLINICAL RECOMMENDATIONS FOR DIAGNOSTICS AND TREATMENT OF IgA-NEPHROPATHY. Nephrology (Saint-Petersburg). 2015;19(6):83-92. (In Russ.)
Просмотров: 6338
Послать статью по эл. почте 